Additionally, trials of oligonucleotide therapeutics and some small-molecule NNMT inhibitors in vitro and in preclinical animal models have validated NNMT as a promising therapeutic target to prevent or treat obesity and related T2D, but currently, clinical trials have not yet been reported. The gene discussed is NNMT; the disease is obesity due to melanocortin 4 receptor deficiency.